Thetis Pharmaceuticals Secures $9M Funding to Advance Novel Oral IBD Treatment
Key Insights
Essex-based Thetis Pharmaceuticals has received $9 million from the Helmsley Charitable Trust to advance TP-317, an innovative oral therapy for inflammatory bowel disease (search).
TP-317, a naturally occurring lipid, aims to reduce inflammation and repair intestinal lining without compromising immune function, offering advantages over current injection-based treatments.
The funding will support a Phase 1b (search) trial of TP-317 in ulcerative colitis (search) patients, building on previous investments totaling over $14 million from the Helmsley Trust.
Thetis Pharmaceuticals LLC, a clinical-stage pharmaceutical company based in Essex, has secured $9 million in loan funding from The Leona M. and Harry B. Helmsley Charitable Trust (search) to advance its innovative oral treatment for inflammatory bowel disease (search) (IBD). The funding will support a Phase 1b (search) trial of TP-317 in ulcerative colitis (search) patients, focusing on establishing safe and effective dosing protocols.
Addressing Critical Unmet Needs in IBD Treatment
The development of TP-317 addresses significant limitations in current IBD treatment options. Existing therapies, primarily administered through injections, often suppress the immune system, leaving patients vulnerable to infections and cancer. Moreover, few patients achieve lasting remission with current treatment approaches for conditions like Crohn's disease (search) and ulcerative colitis (search).
Novel Mechanism of Action
TP-317 represents a breakthrough in IBD treatment approach. As a naturally occurring lipid, the compound works by reducing inflammation and repairing the intestinal lining while preserving the body's natural immune defenses. This dual-action mechanism differentiates it from existing treatments and could potentially offer a safer, more effective option for patients.
Strategic Investment and Development Progress
The Helmsley Charitable Trust has demonstrated strong confidence in TP-317's potential, with total investments now exceeding $14 million. This includes a previous $4.2 million funding round in April 2022, which supported the drug's development for Crohn's disease (search) applications.
Gary Mathias, co-founder and CEO of Thetis, emphasized the significance of the partnership, stating, "Helmsley has been remarkable in supporting our vision for a novel approach that addresses a critical unmet medical need in IBD. We greatly appreciate their support and are excited to advance this unique therapy into patient studies."
Potential Impact on Patient Care
The development of an oral therapy for IBD could significantly improve patient experience and treatment adherence. By eliminating the need for injectable medications and potentially offering a better safety profile, TP-317 might represent a major advancement in IBD treatment options. The upcoming Phase 1b (search) trial will be crucial in validating these potential benefits and establishing the foundation for further clinical development.